Monitoring and managing viral infections in pediatric renal transplant recipients

Pediatric Nephrology

Volumn 27, Issue 5, 2012, Pages 705-717

  Comoli, Patrizia ^a   Ginevri, Fabrizio ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Cellular immunity; Cytomegalovirus; Kidney transplantation; Polyomavirus BK Epstein Barr virus; Quantitative DNA assays

Indexed keywords

ALPHA INTERFERON; ANTIMETABOLITE; ANTIVIRUS AGENT; ARGININE; ARGININE BUTYRATE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PALIVIZUMAB; RIBAVIRIN; RITUXIMAB; SIALIDASE INHIBITOR; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA;

B CELL LYMPHOMA; BK VIRUS; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CHILD; CLINICAL PROTOCOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG LAVAGE; MONITORING; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; POLYOMA VIRUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TREATMENT RESPONSE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS CULTURE; VIRUS INFECTION; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REPLICATION;

BK VIRUS; CHILD; CYTOMEGALOVIRUS INFECTIONS; DISEASE MANAGEMENT; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY TRANSPLANTATION; MONITORING, PHYSIOLOGIC; POLYOMAVIRUS INFECTIONS; VIRUS DISEASES;

EID: 84863455245     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1812-2     Document Type: Review

References (119)

1. Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338:1741-1751 (Pubitemid 28268592)
2. Dharnidharka VR, Stablein DM, Harmon WE (2004) Posttransplant infections now exceed acute rejection as cause for hospitalization: A report of the NAPRTCS. Am J Transplant 4:384-389 (Pubitemid 38282294)
3. Hirsch HH (2005) BK virus: Opportunity makes a pathogen. Clin Infect Dis 41:354-360 (Pubitemid 41022114)
4. Fischer SA (2008) Emerging viruses in transplantation: There is more to infection after transplant than CMV and EBV. Transplantation 86:1327-1339
5. Humar A, Michaels M (2006) American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 6:262
6. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A, Transplantation Society International CMV Consensus Group (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-795
7. Baldanti F, Gatti M, Furione M, Paolucci S, Tinelli C, Comoli P, Merli P, Locatelli F (2008) Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of Tcell depleted HLA-haploidentical stem cell transplantation. J Clin Microbiol 46:3672-3677
8. Nickeleit V, Klimkait T, Binet IF Dalquen P, Del Zenero V, Thiel G, Mihatsch MJ, Hirsch HH (2000) Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 342:1309-1315 (Pubitemid 30408715)
9. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM (2002) Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73:1603-1610 (Pubitemid 34568673)
10. Ginevri F, Hirsch HH, Comoli P (2008) Cellular immune responses to BK virus. Curr Opin Organ Transplant 13:569-574
11. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE (1995) Use of gene-modified virusspecific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-12
12. Choquet S, Leblond V, Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 107:3053-3057
13. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD, Valganciclovir Solid Organ Transplant Study Group (2004) Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611-620 (Pubitemid 38523584)
14. Betts RF, Freeman RB, Douglas RG Jr, Talley TE (1977) Clinical manifestations of renal allograft derived primary cytomegalovirus infection. Am J Dis Child 131:759-763 (Pubitemid 8165827)
15. Rubin RH (1989) The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 261:3607-3609
16. Rubin RH (2007) The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the 'silo hypothesis'. Curr Opin Infect Dis 20:399-407 (Pubitemid 47026238)
17. Kranz B, Vester U, Wingen AM, Nadalin S, Paul A, Broelsch CE, Hoyer PF (2008) Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 12:474-478 (Pubitemid 351652068)
18. Paya CV, Razonable RR (2003) Cytomegalovirus infection after organ transplantation. In:Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections, 2nd Edn. Lippincott, Williams, and Wilkins, pp 298-325
19. Preiksaitis JK, Brennan DC, Fishman J, Allen U (2005) Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5:218-227 (Pubitemid 40179508)
20. Paya CV, Wold AD, Smith TF (1987) Detection of cytomegalovirus infections in specimens other than urine by the shell vial assay and conventional tube cell cultures. J Clin Microbiol 25:755-757 (Pubitemid 17053207)
21. van den Berg AP, Klompmaker IJ, Haagsma EB, Haagsma EB, Scholten-Sampson A, Bijleveld CM, Schirm J, van der Giessen M, Slooff MJ, The TH (1991) Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 164:265-270
22. Locatelli F, Percivalle E, Comoli P, Maccario R, Zecca M, Giorgiani G, De Stefano P, Gerna G (1994) Human cytomegalovirus (HCMV) infection in pediatric patients given allogeneic bone marrow transplantation: Role of early antiviral treatment for HCMVantigenemia on patients' outcome. Br J Haematol 88:64-71 (Pubitemid 24293854)
23. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG (2005) Metaanalysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143:870-880 (Pubitemid 46202222)
24. Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA (2010) Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21:1579-1586
25. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC (2006) Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6:2134-2143 (Pubitemid 44199547)
26. Humar A, Lebranchu Y, Vincenti F, Blumberg E, Punch J, Limaye A, Abramowicz D, Jardine A, Voulgari A, Ives J, Hauser I, Peeters P (2010) The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high risk kidney transplant recipients. Am J Transplant 10:1228-1237
27. San Juan R, Yebra M, Lumbreras C, López-Medrano F, Lizasoain M, Meneu JC, Delgado J, Andrés A, Aguado JM (2009) A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. Clin Transplant 23:666-671
28. Sanghavi SK, Abu-Elmagd K, Keightley MC, St George K, Lewandowski K, Boes SS, Bullotta A, Dare R, Lassak M, Husain S, Kwak EJ, Paterson DL, Rinaldo CR (2008) Relationship of cytomegalovirus load assessed by real-time PCR to pp 65 antigenemia in organ transplant recipients. J Clin Virol 42:335-342
29. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD (2000) Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032-2036 (Pubitemid 30339241)
30. Pescovitz MD, Brook B, Jindal RM, Leapman SB, Milgram MG, Filo RS (1997) Oral ganciclovir in pediatric transplant recipients: A pharmacokinetic study. Clin Transplant 11:613-617 (Pubitemid 27526812)
31. Vaudry W, Ettenger R, Jara P, Varela-Fascinetto G, Bouw MR, Ives J, Walker R, Valcyte WV16726 Study Group (2009) Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 9:636-643
32. Gerna G, Sarasini A, Lilleri D, Percivalle E, Torsellini M, Baldanti F, Revello MG (2003) In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis 188:1639-1647 (Pubitemid 38010673)
33. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M (2000) Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649 (Pubitemid 30627592)
34. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J (2005) Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 79:1277-1286 (Pubitemid 40734783)
35. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP (2005) BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. Kidney Int 68:1834-1839 (Pubitemid 43169929)
36. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR (2002) Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13:2145-2151 (Pubitemid 34790793)
37. Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU (2009) Treatment for BK virus: Incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 22:626-634
38. Hirsch HH, Steiger J (2003) Polyomavirus BK. Lancet Infect Dis 3:611-623 (Pubitemid 37210225)
39. Funk GA, Steiger J, Hirsch HH (2006) Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis 193:80-87 (Pubitemid 43032502)
40. Randhawa PS, Finkelstein S, Scantlebury V, Shapiro R, Vivas C, Jordan M, Picken MM, Demetris AJ (1999) Human Polyoma virus-associated interstial nephritis in the allograft kidney. Transplantation 67:103-109 (Pubitemid 29061146)
41. Drachenberg CB, Papadimitriou JC, Hirsch HH, Wali R, Crowder C, Nogueira J, Cangro CB, Mendley S, Mian A, Ramos E (2004) Histological patterns of polyomavirus nephropathy: Correlation with graft outcome and viral load. Am J Transplantation 4:2082-2092 (Pubitemid 39611638)
42. Ginevri F, Hirsch HH (2008) Polyomavirus-associated nephropathy. In: Molony DA, Craig JC (eds) Evidence-Based Nephrology. John Wiley & Sons, London
43. Acott PD, Hirsch HH (2007) BK virus infection, replication, and diseases in pediatric kidney transplantation. Pediatr Nephrol 22:1243-1250 (Pubitemid 47054911)
44. Dharnidharka VR, Cherikh WS, Abbott KC (2009) An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 87:1019-1026
45. Ginevri F, De Santis R, Comoli P, Pastorino N, Rossi C, Botti G, Fontana I, Nocera A, Cardillo M, Ciardi MR, Locatelli F, Maccario R, Perfumo F, Azzi A (2003) Polyomavirus BK infection in pediatric kidney-allograft recipients: A single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 75:1266-1270 (Pubitemid 36513032)
46. Haysom L, Rosenberg AR, Kainer G, Waliuzzaman ZM, Roberts J, Rawlinson WD, Mackie FE (2004) BK viral infection in an Australian pediatric renal transplant population. Pediatr Transplant 8:480-484 (Pubitemid 39279018)
47. Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, Van Damme-Lombaerts R (2004) Polyomavirus infection in pediatric renal transplant recipients: Evaluation using a quantitative realtime PCR technique. Pediatr Transplant 8:485-492 (Pubitemid 39279019)
48. Alexander RT, Langlois V, Tellier R, Robinson L, Hebert D (2006) The prevalence of BK viremia and urinary viral shedding in a pediatric renal transplant population: A single-center retrospective analysis. Pediatr Transplant 10:586-592
49. Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA (2007) BK virus nephropathy in pediatric renal transplant recipients: An analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2:1037-1042
50. KDIGO Guidelines (2009) Am J Transplant 9(Suppl 3):S44-S58
51. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347:488-496 (Pubitemid 34879336)
52. Hirsch HH Randhawa P, AST Infectious Diseases Community of Practice (2009) BK virus in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S136-S146
53. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA (2005) Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5:582-594 (Pubitemid 40313351)
54. Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, Bodaghi S, Salotti V, Rinieri A, Botti G, Perfumo F, Locatelli F, Comoli P (2007) Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 7:2727-2735 (Pubitemid 350045762)
55. Saad ER, Bresnahan BA, Cohen EP, Lu N, Orentas RJ, Vasudev B, Hariharan S (2008) Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 85:850-854 (Pubitemid 351440750)
56. Vats A, Shapiro R, Singh Randhawa P, Scantlebury V, Tuzuner A, Saxena M, Moritz ML, Beattie TJ, Gonwa T, Green MD, Ellis D (2003) Quantitative viral load monitoring and cidofovir therapy for the management of BK virus associated nephropathy in children and adults. Transplantation 75:105-112 (Pubitemid 36139705)
57. Green M (2001) Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 1:103-108 (Pubitemid 33674148)
58. Opelz G, Dohler B (2003) Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4:222-230
59. Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, Rosato A (2010) The interplay between EBV and the immune system: A rationale for adoptive cell therapy of EBV-related disorders. Haematologica 95:1769-1777
60. Dharnidharka VR, Harmon WE (2001) Management of pediatric postrenal transplantation infections. Semin Nephrol 21:521-531 (Pubitemid 32852770)
61. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80:1233-1243 (Pubitemid 41746802)
62. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE (2001) Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065-1068 (Pubitemid 32448820)
63. Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, Potdar S, Shapiro R, Dharnidharka VR, Kauffman HM (2007) Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 7:2619-2625 (Pubitemid 47561615)
64. McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W, CCTPT Study Group (2008) Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 8:984-989 (Pubitemid 351537758)
65. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, France
66. Cohen JI (2000) Epstein-Barr virus infection. N Engl J Med 343:481-492 (Pubitemid 30646489)
67. Nalesnik M, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J (1988) The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporin A-prednisone immunosuppression. Am J Pathol 133:173-192
68. Baldanti F, Grossi P, Furione M, Simoncini L, Sarasini A, Comoli P, Maccario R, Fiocchi R, Gerna G (2000) High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 38:613-619 (Pubitemid 30082651)
69. Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF (2000) Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response. Blood 96:4055-4063
70. Rowe DT, Webber S, Schauer EM, Reyes J, Green M (2001) Epstein-Barr virus load monitoring: Its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 3:79-87 (Pubitemid 32452922)
71. Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa A, Tomà P, Botti G, Melioli G, Baldanti F, Nocera A, Perfumo F, Ginevri F (2005) Treatment of EBV-related postrenal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 5:1415-1422 (Pubitemid 40839433)
72. Comoli P, Rooney CM (2006) Treatment of Epstein-Barr virus infections. In: Jenson HB, Tselis A (eds) Epstein-Barr virus. Taylor & Francis, New York, pp 351-372
73. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86:3333-3340
74. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E (2002) Post-transplant lymphoproliferative disorders: Improved outcome after clinico-pathologically tailored treatment. Haematologica 87:67-77 (Pubitemid 34101115)
75. Starzl TE, Porter KA, Iwatsuki JT, Rosenthal BW, Shaw RW Jr, Atchison MA, Nalesnik M H, Griffith BP, Hakala TR, Hardesty RL, Jaffe R, Bahnson HT (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporinsteroid therapy. Lancet 1:583
76. Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA (2002) Successful treatment of posttransplant lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ Tcell restoration. Blood 100:2341-2348
77. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109:2571-2578 (Pubitemid 46425904)
78. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC (2005) Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 23:6481-6488 (Pubitemid 46190239)
79. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C (1994) Direct correlation between the load of Epstein-Barr virusinfected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 83:2715-2722 (Pubitemid 24135866)
80. Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M, Wadowsky RM, Rowe DT, Webber SA (2008) Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 8:442-5
81. Lau AH, Soltys K, Sindhi RK, Bond G, Mazareigos G, Green M (2010) Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatr Transplant 14:549-553
82. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G (2009) Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 13:319-323
83. Ginevri F, Di Marco E, Parodi A, Gurrado A, Cirillo C, Botti G, Fontana I, Valente U, Locatelli F, Comoli P (2008) EBV viral load monitoring and reduction of immunosuppression do not successfully prevent PTLD after pediatric kidney transplantation. Am J Transplant 8(s2):477
84. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA (2005) Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 5:2222-2228 (Pubitemid 41648469)
85. Kim Y, Boeckh M, Eglund JA (2007) Community respiratory virus infections in immunocompromised patients: Hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 28:222-242 (Pubitemid 46676916)
86. Kuypers J, Wright N, Ferrenberg J, Huang ML, Cent A, Corey L, Morrow R (2006) Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Microbiol 44:2382-2388 (Pubitemid 44109661)
87. Blanchard SS, Gerrek M, Siegel C, Czinn SJ (2006) Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: Case report and discussion regarding need of routine prophylaxis. Pediatr Transplant 10:826-829 (Pubitemid 44536410)
88. Apalsch AM, Green M, Ledesma-Medina J, Nour B, Wald ER (1995) Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis 20:394-399
89. Ardehall H, Volmar K, Roberts C, Huang ML, Cent A, Corey L, Morrow R (2000) Fatal disseminated adenoviral infection in a renal transplant patient. Transplantation 71:998
90. Shirali GS, Ni J, Chinnock RE, Johnston JK, Rosenthal GL, Bowles NE, Towbin JA (2001) Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 344:1498-1503 (Pubitemid 32429208)
91. Pelaez A, Lyon GM, Force SD, Ramirez AM, Neujahr DC, Foster M, Naik PM, Gal AA, Mitchell PO, Lawrence EC (2009) Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 28:67-71
92. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O (2007) Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 26:1089-1093 (Pubitemid 350190938)
93. McCurdy LH, Milstone A, Dummer S (2003) Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 22:745-753 (Pubitemid 36842926)
94. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127-133 (Pubitemid 32151932)
95. Carter BA, Karpen SJ, Quiros-Tejeira RE, Chang IF, Clark BS, Demmler GJ, Heslop HE, Scott JD, Seu P, Goss JA (2002) Intravenous cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation 74:1050-1052 (Pubitemid 35191260)
96. Thomas NJ, Hollenbeck CS, Ceneviva GD, Geskey JM, Young MJ (2007) Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: A decision analysis model. J Pediatr Hematol/Oncol 29:227-232 (Pubitemid 46597686)
97. Scharpé J, Evenepoel P, Maes B, Bammens B, Claes K, Osterhaus AD, Vanrenterghem Y, Peetermans WE (2008) Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 8:332-337
98. Clark DA, Griffiths PD (2003) Human herpesvirus 6: Relevance of infection in the immunocompromised host. Br J Haematol 120:384-395 (Pubitemid 36241494)
99. Abdel Massih RC, Razonable RR (2009) Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol 15:2561-2569
100. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, Ilstrup D, Paya CV (2001) Human betaherpesvirus interactions in solid organ transplant recipients. J Infect Dis 183:179-184 (Pubitemid 32066016)
101. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV (2005) Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 192:1331-1339 (Pubitemid 41401145)
102. Gupta M, Diaz-Mitoma F, Feber J, Shaw L, Forget C, Filler G (2003) Tissue HHV6 and 7 determination in pediatric solid organ recipients: A pilot study. Pediatr Transplant 7:458-463 (Pubitemid 37466206)
103. Singh N, Carrigan DR (1996) Human Herpesvirus-6 in transplantation: An emerging pathogen. Ann Intern Med 124:1065-1071
104. Nash PJ, Avery RK, Tang WH, Starling RC, Taege AJ, Yamani MH (2004) Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant 4:1200-1203 (Pubitemid 38868616)
105. Montejo M, Ramon Fernandez J, Testillano M, Valdivieso A, Aguirrebengoa K, Varas C, Olaizola A, De Urbina JO (2002) Encephalitis caused by human herpesvirus-6 in a liver transplant recipient. Eur Neurol 48:234-235 (Pubitemid 44858324)
106. Takahashi K, Suzuki M, Iwata Y, Shigeta S, Yamanishi K, De Clercq E (1997) Selective activity of various nucleoside and nucleotide analogues against human herpesvirus 6 and 7. Antivir Chem Chemother 8:24-31 (Pubitemid 27051349)
107. Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF (2000) Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. Blood 95:241-248 (Pubitemid 30017248)
108. Comoli P, Azzi A, Maccario R, Basso S, Botti G, Basile G, Fontana I, Labirio M, Cometa A, Poli F, Perfumo F, Locatelli F, Ginevri F (2004) Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 78:1229-1232 (Pubitemid 39426446)
109. Mattes FM, Vargas A, Kopycinski J, Hainsworth EG, Sweny P, Nebbia G, Bazeos A, Lowdell M, Klenerman P, Phillips RE, Griffiths PD, Emery VC (2008) Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High-Level Replication After Renal Transplantation. Am J Transplant 8:990-999 (Pubitemid 351537766)
110. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A (2009) Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 9:1214-1222
111. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA (2005) Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 5:566-572 (Pubitemid 40313349)
112. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M (2008) PD-1 expression and IL-2 loss of cytomegalovirusspecific T cells correlates with viremia and reversible functional anergy. Am J Transplant 8:1486-1497 (Pubitemid 351989503)
113. Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, Hirsch HH (2007) Polyomavirus BK-specific cellular immune response to VP1 and Large T-antigen in kidney transplant recipients. Am J Transplant 7:1131-1139 (Pubitemid 46643106)
114. Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hariharan S (2008) Recovery of BK virus Large-T-antigen-specific cellular immune response correlates with resolution of BK virus nephropathy. Transplantation 85:185-192 (Pubitemid 351156848)
115. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk HD, Lehmkuhl H, Kern F (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201:1031-1036 (Pubitemid 40524670)
116. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935
117. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038-1044
118. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, Hamprecht K, Handgretinger R, Lang P, Einsele H (2010) Adoptive transfer of pp 65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116:4360-4367
119. Comoli P, Locatelli F, Ginevri F, Maccario R (2002) Cellular immunotherapy for viral infections in solid organ transplant recipients. Curr Opin Organ Transplant 7:314-319